Clinical Trial Update: Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) [Phase 3]

View source ↗

Summary

Phase 3 trial results for Brisdelle (paroxetine mesylate) evaluating efficacy and safety for vasomotor symptoms in postmenopausal women have been completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vasomotor Symptoms

Drugs mentioned

• Brisdelle (paroxetine mesylate)

Snippet

Sponsor: Noven Therapeutics | Conditions: Postmenopausal Symptoms | Phase 3 | Status: COMPLETED | Results posted: 2014-05-20